---
layout: default
title: Ganirelix
parent: 僅模型預測 (L5)
nav_order: 172
evidence_level: L5
indication_count: 10
---

# Ganirelix
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ganirelix: From GnRH Receptor Antagonism to Hypertrichosis

## One-Sentence Summary

Ganirelix is a GnRH (gonadotropin-releasing hormone) receptor antagonist; the original approved indication is not recorded in this evidence pack, and the drug is not currently marketed in Finland. The TxGNN model predicts it may be effective for **Hypertrichosis (disease)**, but this prediction is currently supported by **0 clinical trials** and **0 publications** — it is a pure graph-embedding prediction with no corroborating evidence.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available in evidence pack (no licenses, no indication text on record) |
| Predicted New Indication | Hypertrichosis (disease) |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| Finland Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in structured form for this candidate. Based on general pharmacological knowledge referenced elsewhere in this evidence pack, ganirelix is a GnRH receptor antagonist — a drug class typically used to suppress the hypothalamic-pituitary-gonadal axis (e.g., blocking premature LH surges in controlled ovarian stimulation). No original indication text was captured in this pack, so a direct comparison between the original and predicted indications cannot be made.

For the top-ranked prediction, hypertrichosis, the evidence pack's own mechanistic assessment is explicit: **there is no known pathway connecting GnRH receptor antagonism to excess hair growth pathology.** This is reflected in the ranking as well — while the TxGNN score is high (99.98%), the underlying rank (420th) is far outside the top tier, and zero clinical trials or publications were found on targeted searches. This candidate should be treated as an unvalidated model output rather than a mechanistically grounded hypothesis.

It is also worth noting that among the other nine ranked candidates in this pack, rank 3 ("malformation syndrome with odontal/periodontal component") returned 20 literature hits — but on review these are all generic periodontitis papers with no mention of ganirelix or GnRH signaling, and are flagged in the source data as a likely text-matching artifact rather than genuine evidence. No candidate in this batch has a plausible mechanistic basis or real-world evidence trail.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Finland Market Information

Ganirelix currently holds no marketing authorization in Finland (0 licenses on record); no product/dosage-form information is available.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top predicted indication (hypertrichosis) is supported only by a TxGNN model score, with zero clinical trials, zero publications, and no plausible mechanistic link to GnRH receptor antagonism. Combined with the drug's unmarketed status in Finland and a **Blocking**-severity gap in TFDA/package-insert safety data, this candidate does not meet the minimum evidence bar to advance past initial screening.

**To proceed, the following is needed:**
- Original indication and confirmed mechanism-of-action data for ganirelix (currently absent from this pack)
- TFDA/EMA package insert with warnings and contraindications (Blocking data gap)
- Drug-drug interaction data (currently not found)
- Any preclinical or mechanistic literature specifically linking GnRH receptor antagonism to hair-growth pathology, before further evidence collection is warranted
- Re-evaluation of lower-priority candidates in this batch only if independent (non-text-matching) evidence emerges
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

